Evidence map›Paper›PMID 39990570›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Machine learning models predict long COVID outcomes based on baseline clinical and immunologic factors.

Naresh Doni Jayavelu, Hady Samaha, Sonia Tandon Wimalasena, Annmarie Hoch, Jeremy P Gygi, Gisela Gabernet, Al Ozonoff, Shanshan Liu, Carly E Milliren, Ofer Levy and 40 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

50 authors.

Naresh Doni JayaveluBenaroya Research Institute, University of Washington, Seattle, WA 98101, USA.
Hady SamahaEmory School of Medicine, Atlanta, GA 30322, USA.
Sonia Tandon WimalasenaClinical and Data Coordinating Center (CDCC) Precision Vaccines Program, Boston Children's Hospital, Boston, MA 02115, USA.
Annmarie HochClinical and Data Coordinating Center (CDCC) Precision Vaccines Program, Boston Children's Hospital, Boston, MA 02115, USA.
Jeremy P GygiYale School of Medicine, New Haven, CT 06510, USA.
Gisela GabernetClinical and Data Coordinating Center (CDCC) Precision Vaccines Program, Boston Children's Hospital, Boston, MA 02115, USA.
Al OzonoffClinical and Data Coordinating Center (CDCC) Precision Vaccines Program, Boston Children's Hospital, Boston, MA 02115, USA.
Shanshan LiuClinical and Data Coordinating Center (CDCC) Precision Vaccines Program, Boston Children's Hospital, Boston, MA 02115, USA.
Carly E MillirenClinical and Data Coordinating Center (CDCC) Precision Vaccines Program, Boston Children's Hospital, Boston, MA 02115, USA.
Ofer LevyPrecision Vaccines Program, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Lindsey R BadenBrigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Esther MelamedThe University of Texas at Austin, Austin, TX 78712, USA.
Lauren I R EhrlichThe University of Texas at Austin, Austin, TX 78712, USA.
Grace A McComseyCase Western Reserve University and University Hospitals of Cleveland, Cleveland, OH 44106, USA.
Rafick P SekalyCase Western Reserve University and University Hospitals of Cleveland, Cleveland, OH 44106, USA.
Charles B CairnsDrexel University, Tower Health Hospital, Philadelphia, PA 19104, USA.
Elias K HaddadDrexel University, Tower Health Hospital, Philadelphia, PA 19104, USA.
Joanna SchaenmanDavid Geffen School of Medicine at the University of California Los Angeles, Los Angeles CA 90095, USA.
Albert C ShawYale School of Medicine, New Haven, CT 06510, USA.
David A HaflerYale School of Medicine, New Haven, CT 06510, USA.
Ruth R MontgomeryYale School of Medicine, New Haven, CT 06510, USA.
David B CorryBaylor College of Medicine and the Center for Translational Research on Inflammatory Diseases, Houston, TX 77030, USA.
Farrah KheradmandBaylor College of Medicine and the Center for Translational Research on Inflammatory Diseases, Houston, TX 77030, USA.
Mark A AtkinsonUniversity of Florida, Gainesville, FL 32611, USA.
Scott C BrakenridgeUniversity of Florida, Gainesville, FL 32611, USA.
Nelson I Agudelo HiguitaOklahoma University Health Sciences Center, Oklahoma City, OK 73104, USA.
Jordan P MetcalfOklahoma University Health Sciences Center, Oklahoma City, OK 73104, USA.
Catherine L HoughOregon Health Sciences University, Portland, OR 97239, USA.
William B MesserOregon Health Sciences University, Portland, OR 97239, USA.
Bali PulendranStanford University School of Medicine, Palo Alto, CA 94305, USA.
Kari C NadeauStanford University School of Medicine, Palo Alto, CA 94305, USA.
Mark M DavisStanford University School of Medicine, Palo Alto, CA 94305, USA.
Linda N GengStanford University School of Medicine, Palo Alto, CA 94305, USA.
Ana Fernandez SesmaIcahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Viviana SimonIcahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Florian KrammerIcahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Monica KraftUniversity of Arizona, Tucson AZ 85721, USA.
Chris BimeUniversity of Arizona, Tucson AZ 85721, USA.
Carolyn S CalfeeUniversity of California San Francisco, San Francisco, CA 94115, USA.
David J ErleUniversity of California San Francisco, San Francisco, CA 94115, USA.
Charles R LangelierUniversity of California San Francisco, San Francisco, CA 94115, USA.
IMPACC Network
Leying GuanYale School of Public Health, New Haven, CT 06510, USA.
Holden T MaeckerStanford University School of Medicine, Palo Alto, CA 94305, USA.
Bjoern PetersLa Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Steven H KleinsteinYale School of Medicine, New Haven, CT 06510, USA.
Elaine F ReedDavid Geffen School of Medicine at the University of California Los Angeles, Los Angeles CA 90095, USA.
Joann Diray-ArceClinical and Data Coordinating Center (CDCC) Precision Vaccines Program, Boston Children's Hospital, Boston, MA 02115, USA.
Nadine RouphaelClinical and Data Coordinating Center (CDCC) Precision Vaccines Program, Boston Children's Hospital, Boston, MA 02115, USA.
Matthew C AltmanBenaroya Research Institute, University of Washington, Seattle, WA 98101, USA.

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Using a tonsil organoid system to probe conditions for the induction of protective antibody and T cell responses to influenza.U19AI057229 · NIAID · STANFORD UNIVERSITY · PI Mark Morris Davis · 2003 to 2026
$88.5M
Translation of immunologic technologies from basic research into pre-clinical nonU19AI062629 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI THOMPSON, LINDA F · 2004 to 2023
$56.2M
Systems investigation of vaccine responses in B cell depleted autoimmune patientsU19AI089992 · NIAID · YALE UNIVERSITY · PI David A. Hafler, RUTH R MONTGOMERY · 2010 to 2026
$50.4M
Project 3 - Ex vivo immune profiling of dengue viruses and vaccinesU19AI118610 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KASARSKIS, ANDREW · 2015 to 2021
$46.6M
Systems Biological Analysis of Innate and Adaptive Responses to VaccinationU19AI090023 · NIAID · EMORY UNIVERSITY · PI AHMED, RAFI, LI, SHUZHAO · 2010 to 2021
$45.0M
Understanding Asthma EndotypesU19AI077439 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI David J Erle · 2008 to 2026
$41.1M
Transcriptomics to define biomarkers of neonatal vaccine immunogenicityU19AI118608 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI OZONOFF, AL · 2017 to 2021
$24.7M
Tollip inhibits IL-33 signaling during airway influenza virus infectionU19AI125357 · NIAID · UNIVERSITY OF ARIZONA · PI KRAFT, MONICA · 2016 to 2025
$14.7M
Systems Immunology profiling of respiratory viral infections in vulnerable populationsU19AI167891 · NIAID · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI Matthew C. Altman, Carmen R Mikacenic · 2022 to 2026
$14.0M
Systems biological assessment of T cell responses to vaccinationU19AI167903 · NIAID · STANFORD UNIVERSITY · PI BALI PULENDRAN · 2022 to 2026
$13.2M
Project 3: Mapping the Evolution of Chronic Transplant Injury in the Context of CMV InfectionU19AI128913 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REED, ELAINE F, SARWAL, MINNIE M · 2017 to 2021
$11.2M
NIAID NIH HHS R01 AI104870NIAID NIH HHS R01 AI132774NIAID NIH HHS R01 AI135803NIAID NIH HHS R01 AI145835NIAID NIH HHS U19 AI057229NIAID NIH HHS U19 AI062629NIAID NIH HHS U19 AI077439NIAID NIH HHS U19 AI089992NIAID NIH HHS U19 AI090023NIAID NIH HHS U19 AI118608NIAID NIH HHS U19 AI118610NIAID NIH HHS U19 AI125357NIAID NIH HHS U19 AI128910NIAID NIH HHS U19 AI128913NIAID NIH HHS U19 AI167891NIAID NIH HHS U19 AI167903NIAID NIH HHS U54 AI142766NIH HHS P51 OD011132NIH HHS S10 OD026799
6 · The paper itself

Abstract

The post-acute sequelae of SARS-CoV-2 (PASC), also known as long COVID, remain a significant health issue that is incompletely understood. Predicting which acutely infected individuals will go on to develop long COVID is challenging due to the lack of established biomarkers, clear disease mechanisms, or well-defined sub-phenotypes. Machine learning (ML) models offer the potential to address this by leveraging clinical data to enhance diagnostic precision. We utilized clinical data, including antibody titers and viral load measurements collected at the time of hospital admission, to predict the likelihood of acute COVID-19 progressing to long COVID. Our machine learning models achieved median AUROC values ranging from 0.64 to 0.66 and AUPRC values between 0.51 and 0.54, demonstrating their predictive capabilities. Feature importance analysis revealed that low antibody titers and high viral loads at hospital admission were the strongest predictors of long COVID outcomes. Comorbidities, including chronic respiratory, cardiac, and neurologic diseases, as well as female sex, were also identified as significant risk factors for long COVID. Our findings suggest that ML models have the potential to identify patients at risk for developing long COVID based on baseline clinical characteristics. These models can help guide early interventions, improving patient outcomes and mitigating the long-term public health impacts of SARS-CoV-2.

Indexed as

COVID-19Long COVIDmodelingPASCPatient Reported OutcomesSARS-CoV-2

Identifiers

PMID39990570
PMCPMC11844586

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.